The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2026 | The potential of using CXCL9 as a prognostic indicator following alloSCT
In this video, Shatha Farhan, MD, Henry Ford Health, Detroit, MI, discusses a single-center prospective cohort study (NCT05718791) investigating the potential of using CXCL9, an early inflammatory marker, as a prognostic marker following allogeneic stem cell transplantation (alloSCT). This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is very interesting because when we started studying CXCL9, actually the initial thought was because CXCL9 is a chemokine that’s related to the T-cell differentiation and involved in recruitment of the T-cells. And there are some studies by Dr Luznik and others actually using even machine learning that CXCL9 related around day 28 related to GVHD. When we started this study, we actually knew we’re doing so good in preventing GVHD...
So this is very interesting because when we started studying CXCL9, actually the initial thought was because CXCL9 is a chemokine that’s related to the T-cell differentiation and involved in recruitment of the T-cells. And there are some studies by Dr Luznik and others actually using even machine learning that CXCL9 related around day 28 related to GVHD. When we started this study, we actually knew we’re doing so good in preventing GVHD. The events were so low, but however, there are other studies that related to CXCL9 by Sayed et al. related to inflammaging and related to endovascular aging. Interesting, when we looked at CXCL9 at day 28 plus minus two after transplant, actually the higher CXCL9, which is more than 647, it was associated with worse overall survival with a significant p-value. This is only a small number of patients. These are only around 35 patients or so. But this is an ongoing study. We approved 400 patients, and we’re going to start studying this actually even before the transplant because there’s so much into inflammation and senescence and transplant outcome and relapse mortality.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
